Our Company

About us

Doctor smiling discussing with patients

Visionary Science

Transforming lives with pioneering ocular gene therapy

Beacon Therapeutics is an ophthalmic gene therapy company founded in 2023 to save and restore the vision of patients with a range of prevalent and rare retinal diseases that result in blindness.

We have an established scientific foundation that combines a late-stage development candidate to treat X-linked retinitis pigmentosa (XLRP) with two preclinical programs, one targeting dry age-related macular degeneration (dAMD) and another targeting an inherited cone-rod dystrophy (CRD).

Beacon Therapeutics also has access to a target generation technology platform that will identify, screen and search secreted proteins in the ophthalmology space.

We are supported by funds from Syncona Limited, Forbion, Oxford Science Enterprises, TCGX, Advent Life Sciences, and additional investors.

Father and child building lego structure
Elderly woman smiling while talking to younger woman

Beacon Highlights:

Proprietary pipeline addressing both orphan and prevalent diseases

– Late-stage development candidate to treat X-linked retinitis pigmentosa (XLRP)
– Preclinical programs targeting dry age-related macular degeneration (dry AMD) and cone-rod dystrophy (CRD).

Full R&D-to-clinic capabilities to bring our treatments to patients

– Gene Therapy research teams
– Process and Analytical Development groups
– Regulatory Affairs
– Clinical Development and Clinical Operations

Strategic partnership to secure GMP drug supply

– Beacon commissioned a new state of the art GMP facility in 2023.
– Divested the facility in 2024 and formed a strategic partnership to secure GMP supply of AAV products for tox, clinical and commercial supply.

Executive Team

Lance Baldo

CEO

Image of Dr Abraham Scaria, Chief Scientific Officer at Beacon

Dr Abraham Scaria

Chief Scientific Officer

Ben Rigby

VP, Business Operations

Image of Duncan Whitaker

Duncan Whitaker

SVP, Head of IP and Legal

Thomas Biancardi

Chief Financial Officer

Natasha Jarrett

SVP, Regulatory Affairs

Board of Directors

Image of Dave Fellows, Chief Executive Officer at Beacon

David Fellows

Chairman

Image of Chris Hollowood, the Chairman of Beacon's Board of Directors.

Chris Hollowood

Investor Director

Image of Elisa Petris

Elisa Petris

Investor Director

Dmitrij Hristodorov

Investor Director

Image of Mr Wouter Joustra

Wouter Joustra

Investor Director

Cariad Chester

Investor Director

Image of Katya Smirnyagina

Katya Smirnyagina

Investor Observer

Image of Dominic Schmidt 

Dominic Schmidt 

Investor Observer

Image of Dr. Kaplan, PhD

Lester J. Kaplan

Independent Director

Image of Khurem Farooq

Khurem Farooq

Independent Director

Join us

Make Remarkable Happen

Beacon Therapeutics is always seeking new talent to join our teams and help deliver our mission to save and restore vision to patients with blinding retinal diseases.

If you are interested in joining our team and have the passion, skills and motivation to be a part of this transformational science, then we are keen to hear from you. Please refer to our careers information.

Explore careers
Researcher working in lab, mixing solutions
Man in lab coat working on computer